Abstract
Recurrent respiratory papillomatosis (RRP) is the most common benign
pediatric laryngeal neoplasm. Various adjuvant medical therapies have
failed to reliably decrease surgical frequency in this challenging
airway disease. Recently, systemic bevacizumab has shown promise in
advanced, treatment-resistant papillomatosis. We describe the use of
systemic bevacizumab in two children with severe RRP unresponsive to
other therapies. Voice and breathing improved dramatically in both
patients with minimal side effects. Both patients have not required
surgery in 23 months and 15 months, respectively. Systemic bevacizumab
is a promising long-term treatment for severe RRP, with oncology playing
an important role in patient care.